Authors:
SALEH MN
LEMAISTRE CF
KUZEL TM
FOSS F
PLATANIAS LC
SCHWARTZ G
RATAIN M
ROOK A
FREYTES CO
CRAIG F
REUBEN J
SAMS MW
NICHOLS JC
Citation: Mn. Saleh et al., ANTITUMOR-ACTIVITY OF DAB(389)IL-2 FUSION TOXIN IN MYCOSIS-FUNGOIDES, Journal of the American Academy of Dermatology, 39(1), 1998, pp. 63-73
Authors:
LEMAISTRE CF
SALEH MN
KUZEL TM
FOSS F
PLATANIAS LC
SCHWARTZ G
RATAIN M
ROOK A
FREYTES CO
CRAIG F
REUBEN J
NICHOLS JC
Citation: Cf. Lemaistre et al., PHASE-I TRIAL OF A LIGAND FUSION-PROTEIN (DAB(389)IL-2) IN LYMPHOMAS EXPRESSING THE RECEPTOR FOR INTERLEUKIN-2, Blood, 91(2), 1998, pp. 399-405
Authors:
NICHOLS J
FOSS F
KUZEL TM
LEMAISTRE CF
PLATANIAS L
RATAIN MJ
ROOK A
SALEH M
SCHWARTZ G
Citation: J. Nichols et al., INTERLEUKIN-2 FUSION PROTEIN - AN INVESTIGATIONAL THERAPY FOR INTERLEUKIN-2 RECEPTOR-EXPRESSING MALIGNANCIES, European journal of cancer, 33, 1997, pp. 34-36
Authors:
LIEPA A
BENNETT CL
YARNOLD PR
ENAS N
LOZANO J
KUZEL T
OLSON E
MARTIN A
KIM Y
DUVIC M
FRANKEL A
VONDERHEID E
BOWEN G
JEGASOTHY B
WOOD G
GORDON M
PINTERBROWN L
FIVENSON D
HEALD P
OSCROFF A
FOSS F
GLODE M
STEWART S
MOLINA A
KNOBLER E
NICHOLS J
Citation: A. Liepa et al., CHANGES IN QUALITY-OF-LIFE (QOL) FOR PATIENTS (PTS) ENROLLED IN A PHASE-III TRIAL OF TREATMENT WITH A DIPHTHERIA-TOXIN FUSION PROTEIN (DAB(389)IL-2) FOR MYCOSIS-FUNGOIDES (MF), Blood, 90(10), 1997, pp. 3924-3924
Authors:
BACHA P
FOWLIE A
GRIMALDO D
HILLIER J
OLSEN E
MARTIN A
KIM Y
DUVIC M
FRANKEL A
VONDERHEID E
BOWEN G
JEGASOTHY B
WOOD G
GORDON M
PINTERBROWN L
FIVENSON D
HEALD P
OSEROFF A
KUZEL T
FOSS F
GLODE M
STEWART S
MOLINA A
KNOBLER E
Citation: P. Bacha et al., ANTIBODY AND PHARMACOKINETIC ANALYSIS FROM A PIVOTAL TRIAL OF ONTAK(TM) (DAB(389)IL-2) FOR THE TREATMENT OF CUTANEOUS T-CELL LYMPHOMA (CTCL), Blood, 90(10), 1997, pp. 1457-1457
Authors:
KUZEL T
OLSEN E
MARTIN A
KIM Y
DUVIC M
FRANKEL A
VONDERHEID E
BOWEN G
JEGASOTHY B
WOOD G
GORDON M
PINTERBROWN L
FIVENSON D
HEALD P
OSEROFF A
FOSS F
GLODE M
STEWART S
MOLINA A
KNOBLER E
NICHOLS J
BACHA P
Citation: T. Kuzel et al., PIVOTAL PHASE-III TRIAL OF 2 DOSE LEVELS OF DAB(389)IL-2 (ONTAK(TM)) FOR THE TREATMENT OF MYCOSIS-FUNGOIDES (MF), Blood, 90(10), 1997, pp. 2607-2607
Authors:
BOGEN SA
PELLEY D
CHARIF M
MCCUSKER M
KOH H
FOSS F
GARIFALLOU M
ARKIN C
ZUCKERFRANKLIN D
Citation: Sa. Bogen et al., IMMUNOPHENOTYPIC IDENTIFICATION OF SEZARY CELLS IN PERIPHERAL-BLOOD, American journal of clinical pathology, 106(6), 1996, pp. 739-748
Citation: Ml. Rivo et al., PRIMARY-CARE AND THE EDUCATION OF THE GENERALIST PHYSICIAN - COMING OF AGE - INTRODUCTION, Academic medicine, 70(1), 1995, pp. 3-4
Authors:
BERGER BM
NAADIMUTKU A
BODDY A
FISHER HA
MCCONNELL JD
MILAM D
MOBLEY D
RAJFER J
ADAMS G
AIGEN AB
BOYD S
NARAYAN P
ANDRIOLE G
BAHNSON R
BELVILLE W
TOPLEY HM
BLOCK N
EPSTEIN HB
LAZAN DW
BAKULE PT
BOYLE ET
FERRIGNI R
BRANNAN W
BRAWER MK
FOSS F
COX CE
SMITH J
ELHILALI M
GOLDENBERG L
SULLIVAN L
NORMAN R
LAWEN JG
TRACHTENBERG J
LEPOR H
KANDZARI S
LABASKY R
KALISH M
PICKETT SH
Citation: Bm. Berger et al., THE EFFECT OF ZANOTERONE, A STEROIDAL ANDROGEN RECEPTOR ANTAGONIST, IN MEN WITH BENIGN PROSTATIC HYPERPLASIA, The Journal of urology, 154(3), 1995, pp. 1060-1064
Authors:
PINCUS S
OSEROFF A
BRENEMAN D
FOSS F
KOH H
DUVIC M
VONDERHEID E
COE B
PHILLIPS SB
BERNSTEIN JE
Citation: S. Pincus et al., EFFECTIVENESS OF TOPICAL NALOXONE, AN OPIOID ANTAGONIST, IN THE TREATMENT OF PRURITUS ASSOCIATED WITH MYCOSIS-FUNGOIDES (MF) AND SEZARY-SYNDROME (SS), Journal of investigative dermatology, 104(4), 1995, pp. 661-661
Authors:
KUZEL T
FOSS F
LEMAISTRE C
PLATANIAS L
RATAIN M
ROOK A
SALEH M
SCHWARTZ G
NICHOLS J
Citation: T. Kuzel et al., PHASE-I TRIAL OF A DIPHTHERIA-TOXIN (DT) FUSION PROTEIN (DAB(389)IL-2) FOR THE TREATMENT OF INTERLEUKIN-2 RECEPTOR (IL-2R) EXPRESSING HEMATOLOGIC NEOPLASMS, Blood, 86(10), 1995, pp. 1081-1081
Authors:
THAKUR S
LIN HC
TSENG WT
KUMAR S
BRAVO R
FOSS F
GELINAS C
RABSON AB
Citation: S. Thakur et al., REARRANGEMENT AND ALTERED EXPRESSION OF THE NFKB-2 GENE IN HUMAN CUTANEOUS T-LYMPHOMA CELLS, Oncogene, 9(8), 1994, pp. 2335-2344
Authors:
LEMAISTRE CF
KUZEL T
FOSS F
HESKETH P
SALEH M
PLATANIAS L
SCHWARTZ G
CRAIG F
TOLSON K
WOODWORTH T
Citation: Cf. Lemaistre et al., DAB389IL-2 IS WELL TOLERATED AT DOSES INDUCING RESPONSE IN IL-2 RECEPTOR-EXPRESSING LYMPHOMAS, Blood, 82(10), 1993, pp. 10000137-10000137